OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma

Enhanced type 2 helper T (Th2) cell responses to inhaled harmless allergens are strongly associated with the development of allergic diseases. Antigen formulated with an appropriate adjuvant can elicit suitable systemic immunity to protect individuals from disease. Although much has been learned abo...

Full description

Saved in:
Bibliographic Details
Main Authors: Cheng-Jang Wu, Pin-Hsun Tseng, Cheng-Chi Chan, Sara Quon, Li-Chen Chen, Ming-Ling Kuo
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2018/1697276
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832558830240661504
author Cheng-Jang Wu
Pin-Hsun Tseng
Cheng-Chi Chan
Sara Quon
Li-Chen Chen
Ming-Ling Kuo
author_facet Cheng-Jang Wu
Pin-Hsun Tseng
Cheng-Chi Chan
Sara Quon
Li-Chen Chen
Ming-Ling Kuo
author_sort Cheng-Jang Wu
collection DOAJ
description Enhanced type 2 helper T (Th2) cell responses to inhaled harmless allergens are strongly associated with the development of allergic diseases. Antigen formulated with an appropriate adjuvant can elicit suitable systemic immunity to protect individuals from disease. Although much has been learned about Th1-favored immunomodulation of OK-432, a streptococcal preparation with antineoplastic activity, little is known about its adjuvant effect for allergic diseases. Herein, we demonstrate that OK-432 acts as an adjuvant to favor a systemic Th1 polarization with an elevation in interferon- (IFN-) γ and ovalbumin- (OVA-) immunoglobulin (Ig) G2a. Prior vaccination with OK-432 formulated against OVA attenuated lung eosinophilic inflammation and Th2 cytokine responses that were caused by challenging with OVA through the airway. This vaccination with OK-432 augmented the ratios of IFN-γ/interleukin- (IL-) 4 cytokine and IgG2a/IgG1 antibody compared to the formulation with Th2 adjuvant aluminum hydroxide (Alum) or antigen only. The results obtained in this study lead us to propose a potential novel adjuvant for clinical use such as prophylactic vaccination for pathogens and immunotherapy in atopic diseases.
format Article
id doaj-art-d91ceb7c4d6c4b67ac42e1e3cae19148
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-d91ceb7c4d6c4b67ac42e1e3cae191482025-02-03T01:31:28ZengWileyJournal of Immunology Research2314-88612314-71562018-01-01201810.1155/2018/16972761697276OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of AsthmaCheng-Jang Wu0Pin-Hsun Tseng1Cheng-Chi Chan2Sara Quon3Li-Chen Chen4Ming-Ling Kuo5Chang Gung Molecular Medicine Research Center, Chang Gung University, Taoyuan, TaiwanGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, TaiwanGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, TaiwanDivision of Biological Sciences, University of California, San Diego, La Jolla, CA 92093, USADivision of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, TaiwanDivision of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, TaiwanEnhanced type 2 helper T (Th2) cell responses to inhaled harmless allergens are strongly associated with the development of allergic diseases. Antigen formulated with an appropriate adjuvant can elicit suitable systemic immunity to protect individuals from disease. Although much has been learned about Th1-favored immunomodulation of OK-432, a streptococcal preparation with antineoplastic activity, little is known about its adjuvant effect for allergic diseases. Herein, we demonstrate that OK-432 acts as an adjuvant to favor a systemic Th1 polarization with an elevation in interferon- (IFN-) γ and ovalbumin- (OVA-) immunoglobulin (Ig) G2a. Prior vaccination with OK-432 formulated against OVA attenuated lung eosinophilic inflammation and Th2 cytokine responses that were caused by challenging with OVA through the airway. This vaccination with OK-432 augmented the ratios of IFN-γ/interleukin- (IL-) 4 cytokine and IgG2a/IgG1 antibody compared to the formulation with Th2 adjuvant aluminum hydroxide (Alum) or antigen only. The results obtained in this study lead us to propose a potential novel adjuvant for clinical use such as prophylactic vaccination for pathogens and immunotherapy in atopic diseases.http://dx.doi.org/10.1155/2018/1697276
spellingShingle Cheng-Jang Wu
Pin-Hsun Tseng
Cheng-Chi Chan
Sara Quon
Li-Chen Chen
Ming-Ling Kuo
OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma
Journal of Immunology Research
title OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma
title_full OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma
title_fullStr OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma
title_full_unstemmed OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma
title_short OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma
title_sort ok 432 acts as adjuvant to modulate t helper 2 inflammatory responses in a murine model of asthma
url http://dx.doi.org/10.1155/2018/1697276
work_keys_str_mv AT chengjangwu ok432actsasadjuvanttomodulatethelper2inflammatoryresponsesinamurinemodelofasthma
AT pinhsuntseng ok432actsasadjuvanttomodulatethelper2inflammatoryresponsesinamurinemodelofasthma
AT chengchichan ok432actsasadjuvanttomodulatethelper2inflammatoryresponsesinamurinemodelofasthma
AT saraquon ok432actsasadjuvanttomodulatethelper2inflammatoryresponsesinamurinemodelofasthma
AT lichenchen ok432actsasadjuvanttomodulatethelper2inflammatoryresponsesinamurinemodelofasthma
AT minglingkuo ok432actsasadjuvanttomodulatethelper2inflammatoryresponsesinamurinemodelofasthma